RecruitingPhase 1NCT07049328
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
A Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata
Sponsor
HCW Biologics
Enrollment
30 participants
Start Date
Aug 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called HCW9302, an IL-2 fusion protein for people with alopecia areata (aa). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 70 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGHCW9302, an IL-2 fusion protein
Injection
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07049328
Related Trials
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT068261967 locations
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
NCT073815561 location
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
NCT067995206 locations